0 CHECKOUT

Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2016

  • ID: 3517959
  • December 2015
  • Region: Cambodia, Laos
  • 74 pages
  • Business Monitor International
1 of 4

While the underdeveloped nature of its pharmaceutical and health care sector will bring about commercial benefits for foreign investors, competition from relatively low risk and higher rewards markets such as Vietnam means that Cambodia will remain low on investors'' priority list.

Headline Expenditure Projections
- Pharmaceuticals: KHR910.8bn (USD228mn) in 2014 to KHR1,008.1bn (USD252mn) in 2015; +10.7%
in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.

- Healthcare: KHR5,119.8bn (USD1.3mn) in 2014 to KHR5,676.2bn (USD1.4mn) in 2015; +10.9% in local currency terms and US dollar terms. Forecast unchanged from previous quarter.

Note: Product cover images may vary from those shown
2 of 4

Table: Headline Pharmaceuticals & Healthcare Forecasts (Cambodia 2013-2019) 7

SWOT 9

Industry Forecast 11

Pharmaceutical Market Forecast 11

Latest Trend 11

Structural Trends 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2011-2019) 12

Healthcare Market Forecast 14

Structural Trends 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2011-2019) 17

Pharmaceutical Trade Forecast 18

Structural Trends 18
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2013-2019) 19

Pharmaceuticals & Healthcare Risk/Reward Index 20

Asia Pacific Risk/Reward Index 20

Cambodia Risk/Reward Index 27

Rewards 27

Risks 27

Market Overview 29

Healthcare Sector 30

Health Insurance 31

Research & Development 32

Clinical Trials 33

Epidemiology 34

Regulatory Review 36

Regulatory Regime 36

Intellectual Property Issues 36

Counterfeit Medicines 37

Pricing And Reimbursement 39

Competitive Landscape 40

Pharmaceutical Sector 40

Company Developments 42
Table: Multinational Market Activity 42

Pharmaceutical Wholesale 43

Pharmaceutical Retail 43

Company Profile 45

Pfizer 45

PharmaProduct Manufacturing (PPM) 47

Sanofi 50

Demographic Forecast 53
Table: Population Headline Indicators (Cambodia 1990-2025) 54
Table: Key Population Ratios (Cambodia 1990-2025) 54
Table: Urban/Rural Population & Life Expectancy (Cambodia 1990-2025) 55
Table: Population By Age Group (Cambodia 1990-2025) 55
Table: Population By Age Group % (Cambodia 1990-2025) 56

Demographic Forecast 58
Table: Population Headline Indicators (Laos 1990-2025) 59
Table: Key Population Ratios (Laos 1990-2025) 59
Table: Urban/Rural Population & Life Expectancy (Laos 1990-2025) 60
Table: Population By Age Group (Laos 1990-2025) 60
Table: Population By Age Group % (Laos 1990-2025) 61

Demographic Forecast 63
Table: Population Headline Indicators (Myanmar 1990-2025) 64
Table: Key Population Ratios (Myanmar 1990-2025) 64
Table: Urban/Rural Population & Life Expectancy (Myanmar 1990-2025) 65
Table: Population By Age Group (Myanmar 1990-2025) 65
Table: Population By Age Group % (Myanmar 1990-2025) 66

Glossary 68

Methodology 70

Pharmaceutical Expenditure Forecast Model 70

Healthcare Expenditure Forecast Model 70

Notes On Methodology 71

Risk/Reward Index Methodology 72

Index Overview 73
Table: Pharmaceutical Risk/Reward Index Indicators 73

Indicator Weightings 74

Note: Product cover images may vary from those shown
3 of 4

Pfizer
PharmaProduct Manufacturing (PPM)
Sanofi

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S